Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics Inc (NQ: MYGN )

13.34 USD +0.33 (+2.54%)
Official Closing Price Updated: 5:07 PM EDT, Oct 20, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Myriad Genetics Inc

< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate Governance Changes In Support of Stakeholder Interests
From GlobeNewswire News Releases
Myriad Genetics and Sandstone Diagnostics Form Point-of-Care Blood Collection Partnership
Tags c:united/kingdom s:california business/economy
From EIN Presswire
Myriad Genetics Expands Board of Directors with New Member
Rashmi Kumar Elected to Myriad’s Board of Directors 
From GlobeNewswire News Releases
American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer
From GlobeNewswire News Releases
Myriad Genetics Announces Inducement Awards
From GlobeNewswire News Releases
Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of Directors
From GlobeNewswire News Releases
Myriad Genetics Reports Fiscal Fourth-Quarter 2020 Financial Results
From GlobeNewswire News Releases
New Study Shows Screening Based on Self-Reported Ethnicity Fails to Identify Significant Percentage of Pregnancies Affected by Serious Genetic Conditions
From GlobeNewswire News Releases
Myriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020 Financial Results on August 13, 2020
From GlobeNewswire News Releases
Medicare Expands Coverage for BRACAnalysis® CDx in Prostate Cancer
From GlobeNewswire News Releases
Expected Growth in Cancer Cases Reinforces Need for Superior Diagnostic Options
FinancialBuzz.com News Commentary 
From PR Newswire
Myriad Launches Proprietary AMPLIFY™ Technology, Further Increasing the Performance of its Prequel™ NIPS Test
From GlobeNewswire News Releases
Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra®
From GlobeNewswire News Releases
Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D.
From GlobeNewswire News Releases
Inmedix welcomes Bernie Tobin, former President of Crescendo Bioscience (Myriad Genetics) to its Board of Directors
Tags healthcare/pharmaceuticals h:worldnews technology
From EIN Presswire
Myriad Announces New Studies Validating the Ability of Myriad’s riskScore® Test to Modify Breast Cancer Risk Prediction
Publications Demonstrate the Ability of the PRS Component of riskScore® to Accurately Stratify Breast Cancer Risk in Women Both With and Without Pathogenic Mutations 
From GlobeNewswire News Releases
Myriad Announces Partnership with OptraHEALTH® to Deliver “Gene™” a New AI Based Information Tool for Hereditary Cancer Patients
From GlobeNewswire News Releases
Myriad Launches New GeneSight® Psychotropic Patient Collection Kit
Clinicians Seeing Patients Remotely Can Now Offer Home DNA Sample Collection 
From GlobeNewswire News Releases
New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological Assessment
From GlobeNewswire News Releases
Myriad Announces New Favorable Coverage Policies for Prolaris® from Three New Commercial Health Plans Including Major National Provider
From GlobeNewswire News Releases
Palmetto GBA Issues Final Local Coverage Determination on Pharmacogenomic Testing for Medicare Beneficiaries
New LCD Provides Coverage for PGx Testing Across a Broad Range of Providers and Psychiatric Conditions 
From GlobeNewswire News Releases
New Study Demonstrates GeneSight Psychotropic Better Predicts Blood Drug Levels When Compared to Single-Gene Testing
Study Reviewed Citalopram and Escitalopram 
From GlobeNewswire News Releases
Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict® Test in Women with Early-Stage Breast Cancer
EndoPredict Predicts Response to Neoadjuvant Chemotherapy and Endocrine Therapy 
From GlobeNewswire News Releases
Myriad Presents New Data at ASCO Validating the Ability of riskScore® to Provide Personalized Breast Cancer Risk Information to Patients
From GlobeNewswire News Releases
Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T. Henderson, M.D.
From GlobeNewswire News Releases
Cerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study
From GlobeNewswire News Releases
Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer
From GlobeNewswire News Releases
Thinking about buying stock in Aurora Cannabis, Cytokinetics, Quotient, Myriad Genetics, or Avaya Holdings?
InvestorsObserver issues critical PriceWatch Alerts for ACB, CYTK, QTNT, MYGN, and AVYA. 
From PR Newswire
Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer
From GlobeNewswire News Releases
Myriad Genetics Reports Fiscal Third-Quarter 2020 Financial Results
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.